This site is intended for healthcare professionals

Incyte announces the FDA has extended the sNDA review period for ruxolitinib in chronic graft-versus-host disease (GVHD),

Read time: 1 mins
Last updated:10th Jun 2021
Published:10th Jun 2021
Incyte announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for ruxolitinib (Jakafi) for the treatment of adult and pediatric patients 12 years and older with steroid-refractory chronic graft-versus-host disease (GVHD).
Condition: Graft-v-Host Disease (GvHD)
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest